First patient enters Oncopeptides study aiming to gain real-world insights from Pepaxti in Germany

On July 22, 2024 Oncopeptides, a biotech company focused on difficult-to-treat cancers, reported entry of the first patient in a new study evaluating the real-world effectiveness and safety of Pepaxti in German patients (Press release, Oncopeptides, JUL 22, 2024, View Source [SID1234646794]). The study, which will include 100 patients across around 50 sites in Germany, aims at gathering evidence on Pepaxti’s effectiveness and safety in a real-world clinical practice and is the first Pepaxti study engaging treating physicians at multiple German sites.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study, named HARBOUR, will assess real-life clinical outcomes of Pepaxti treatment of patients suffering from refractory, relapsed multiple myeloma (RRMM) in a patient population that mirrors the indication of Pepaxti. The study marks another step forward in Oncopeptides’ ongoing efforts to strengthen the medical understanding of Pepaxti and will support the evidence base for the Pepaxti indicated population.

"Initiating the HARBOUR study with the enrollment of the first patient is a pivotal step forward to address the unmet needs of RRMM patients," says Dr. med. Johannes Waldschmidt, the Scientific Leader of the study from Universitätsklinikum Würzburg, Germany. "This partnership with Oncopeptides offers an opportunity for the German medical community to contribute to significant advancements in myeloma treatment and patient care."

"Our aim is to understand the performance of Pepaxti in the real world. It is important evidence to generate, not only for the German market but for the full European commercialization," says Sofia Heigis, CEO of Oncopeptides. "We are happy to for the first time initiate a study across Germany and also the very first study that is fully focused on our target population."

For more information, please visit the German Clinical Trials Register or Oncopeptides’ web site where questions and answers for investors will also be published.